Novel antiviral drug combinations demonstrate COVID-19 therapeutic potential

Researchers demonstrate that combinations of antiviral drugs inhibiting both polymerase and exonuclease reduce SARS-CoV-2 replication 10 times more than polymerase inhibitors alone.